4.5 Article

Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression

Journal

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2018.04.027

Keywords

Mild asthma; Prognosis; Natural history; Disease progression; Risk factors; Rescue medication; Controller medication

Funding

  1. AstraZeneca Canada through the University-Industry-Liaison Office of the University of British Columbia

Ask authors/readers for more resources

BACKGROUND: Most patients with asthma have mild disease. However, the clinical course of mild asthma and risk factors for progression are not well studied. OBJECTIVE: To examine the long-term trajectories of mild asthma and the effects of early-stage risk factors on the subsequent disease course. METHODS: From the administrative health data of British Columbia, Canada, we identified patients aged 14 to 45 years with newly diagnosed mild asthma between January 1997 and December 2012. For each follow-up year, we categorized a patient's asthma severity into mild/dormant, moderate, or severe on the basis of the intensity of asthma medications and occurrence of exacerbations. Ordinal logistic regression was used to estimate the probability of severity or all-cause death in the next year as a function of a patient's severity history in the past 3 years and selected baseline risk factors. RESULTS: The study included 70,829 patients with incident mild asthma (62% women; mean age, 31 years). Over 10 years, 8% of these patients transitioned tomoderate or severe asthma. Inappropriate use of rescue medications and older age were the most influential determinants for progression from mild asthma (odds ratios, 1.79; 95% CI, 1.68-1.90; P <.001; 1.24 per 10-year increase in age; 95% CI, 1.22-1.27; P <.001), whereas the presence of allergic rhinitis had no significant effects (odds ratio, 0.95; 95% CI, 0.91-1.00; P =. 063). CONCLUSIONS: Mild asthma remains largely stable over time. However, potentially modifiable factors such as inappropriate use of rescue medications are associated with a worsened prognosis. (C) 2018 American Academy of Allergy, Asthma & Immunology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available